06/25/22 9:05 AMNasdaq : IONS clinical trialIonis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™- Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B- Phase 3 clinical study evaluating b epirovirsen as a monotherapy is anticipated to start in the first half of 2023- GSK to explore potentialRHEA-AIneutral
06/21/22 2:00 AMNasdaq : IONS clinical trialIonis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)IonisRHEA-AIvery positive
06/13/22 7:05 AMNasdaq : IONS Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDAIonis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, anRHEA-AIpositive
06/03/22 5:20 AMNasdaq : IONS clinical trialIonis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patientsTwelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatalRHEA-AIneutral
05/12/22 7:05 AMNasdaq : IONS conferencesIonis to present at RBC Capital Markets Global Healthcare ConferenceIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.A live webcast and additional information about this presentation can beRHEA-AIneutral
05/04/22 7:00 AMNasdaq : IONS earningsIonis reports first quarter financial results and recent business achievementsIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements."We are offRHEA-AIpositive
05/02/22 7:05 AMNasdaq : IONS conferencesIonis to host 2022 virtual Annual Meeting of StockholdersIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.The agenda for the event is as follows:- 5:00RHEA-AIneutral
04/20/22 7:05 AMNasdaq : IONS earningsIonis to hold first quarter 2022 financial results webcastIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4 th at 11:30 a.m. Eastern Time to discuss its first quarter financialRHEA-AIneutral
04/04/22 12:15 AMNasdaq : IONS clinical trialIonis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated- ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen- Study findings warrant further clinical development ofRHEA-AIneutral
03/28/22 7:30 AMNasdaq : IONS, BIIB clinical trialBiogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral SclerosisBIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS) , did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapiesRHEA-AIneutral